OCMS Bio
- Company typePrivate
- Founded2017
- HeadquartersMalvern, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
OCMS Bio firmographics
Firmographics- Name
- OCMS Bio
- Legal name
- OCMS Bio, LLC
- Website
- https://ocms.bio
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
OCMS Bio industry classification
Industry- Product category
- Therapeutic Antibody Discovery and Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where OCMS Bio is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OCMS Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Therapeutic Antibody Development and Licensing: OCMS Bio develops proprietary antibody therapeutics through its pipeline (OB-24-01, OB-24-02, OB-25-01, OB-25-02) targeting infectious diseases, metabolism, oncology, and autoimmune disorders. Revenue would be generated through licensing deals, partnerships with pharmaceutical companies, or eventual product commercialization.
- Technology Platform Partnerships: The company offers access to its OCMS platform technology for pharmaceutical partners seeking accelerated antibody discovery services, generating revenue through platform licensing and collaboration agreements.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
OCMS Bio product offering
Product offeringCore offering
OCMS Bio discovers and develops therapeutic monoclonal antibodies using its proprietary OCMS (On-Cell mAb Screening) platform combined with AI-designed de novo antibody libraries. The company operates a preclinical pipeline of four candidates and provides pharmaceutical partners with access to its discovery platform and antibody assets through licensing arrangements.
Product overview
OCMS Bio is an antibody discovery and engineering company offering a unified platform plus pipeline products. The core offering is the On-Cell mAb Screening (OCMS) Platform, a proprietary high-throughput mammalian cell-based screening technology that identifies antibodies based on functional activity rather than traditional binding affinity metrics. This platform enables screening of 100,000+ antibody variants in parallel while preserving native heavy-light chain pairings. The company's pipeline includes four therapeutic candidates: OB-24-01 (long-acting RSV antibody), OB-24-02 (ActRIIA/B targeting metabolism antibody), OB-25-01 (undisclosed orphan drug), and OB-25-02 (undisclosed oncology ADC). The platform and pipeline products are integrated through the company's function-first discovery approach designed to generate best-in-class biologics.
Differentiator
Problem solved
Functional benefit
Products and services
- OCMS Antibody Discovery Platform Proprietary on-cell monoclonal antibody screening service that screens antibody candidates directly against targets in their native cell-surface context, available to pharmaceutical and biotechnology partners for outsourced discovery campaigns.
- AI-Designed De Novo Antibody Libraries
- OB-24-01 (RSV Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting respiratory syncytial virus (RSV), available for out-licensing to pharmaceutical partners.
- OB-24-02 (ActRIIA/B Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting ActRIIA/B receptors for metabolic disease applications, available for out-licensing to pharmaceutical partners.
- OB-25-01 (Rare Autoimmune Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting a rare autoimmune indication with orphan drug potential, available for out-licensing to pharmaceutical partners.
- OB-25-02 (Oncology ADC Candidate) Preclinical-stage antibody candidate developed as an antibody-drug conjugate (ADC) for oncology applications, available for out-licensing to pharmaceutical partners.
Quantifiable outcome
- Screens 100,000+ antibody variants in parallel
- +2 more outcomes
Companies that use OCMS Bio
Customer profileSegments2 records
Ideal customer profiles1 record
OCMS Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OCMS Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Partner Company (Undisclosed)coreOCMS Bio collaborated with a partner company to successfully screen a large AI-designed antibody library, demonstrating the power of its On-Cell mAb Screening (OCMS) platform to accelerate antibody discovery. This collaboration provided critical insights into antibody ranking, function, and further refinement of AI-driven design methodologies.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
OCMS Bio competitors and assessment
Company assessmentDirect peers
- Absci: Public AI-driven generative antibody design company combining zero-shot AI design with high-throughput wet-lab validation. Comparable as a direct competitor using AI + high-throughput screening to accelerate therapeutic antibody discovery.
- BigHat Biosciences: AI/ML-driven antibody design and discovery platform integrating generative AI with high-throughput laboratory screening. Comparable emerging player pursuing similar AI + functional screening thesis.
- AbCellera Biologics: NASDAQ-listed antibody discovery platform combining high-throughput single-cell screening with AI/ML for therapeutic antibody identification. Directly comparable as a platform-first antibody discovery company pursuing pharma partnerships and an internal pipeline.
- Adimab: Leading independent antibody discovery platform offering yeast-based and mammalian-based discovery services to pharma partners. Closely comparable as a platform-licensing antibody discovery business with a similar B2B pharma partnership GTM motion.
- Alloy Therapeutics: Biotech platform company providing antibody discovery services, libraries, and licensing infrastructure to pharma and biotech partners. Comparable as a B2B antibody discovery platform with licensing-driven revenue model.
Broad incumbents
- GenScript: Global biotech providing antibody discovery, protein engineering, and CDMO services alongside broader gene synthesis. Comparable as an incumbent offering antibody discovery services and platform partnerships to pharma/biotech.
- Bio-Techne: Large public life-sciences tools and reagents company with significant antibody-related reagents, assays, and discovery services. Comparable as an incumbent providing antibody research tools and adjacent services to pharma/biotech customers.
Emerging players
- Ginkgo Bioworks: Public synthetic biology platform offering cell engineering and bioprocessing services to pharma and industrial biotech customers. Comparable as a platform-as-a-service biotech pursuing pharma partnerships, though broader than pure antibody discovery.
- Generate Biomedicines: Generative AI biologics platform developing de novo protein therapeutics, including antibodies. Comparable as an emerging AI-driven biologic discovery company with both partnered and internal programs.
- Immunome: NASDAQ-listed antibody discovery and development company co-founded by OCMS founder Dr. Scott Dessain. Comparable as an antibody-focused clinical-stage company that emerged from similar scientific leadership, providing a reference point for the founder's prior playbook.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
OCMS Bio social profiles
Digital presenceOCMS Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
OCMS Bio leadership team
Management profileNumber of profiles
Profiles5 records
OCMS Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OCMS Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OCMS Bio
What does OCMS Bio do?
OCMS Bio discovers and develops therapeutic monoclonal antibodies using its proprietary OCMS (On-Cell mAb Screening) platform combined with AI-designed de novo antibody libraries. The company operates a preclinical pipeline of four candidates and provides pharmaceutical partners with access to its discovery platform and antibody assets through licensing arrangements.
Is OCMS Bio a public or private company?
OCMS Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OCMS Bio founded?
OCMS Bio was founded in 2017. It employs 1 to 10 people.
Where is OCMS Bio based?
OCMS Bio is headquartered in Malvern, United States, in the North America region.
How does OCMS Bio make money?
Two revenue lines are on record. Therapeutic Antibody Development and Licensing is the primary driver. The others are technology Platform Partnerships.
Who are OCMS Bio's main competitors?
Direct peers on record are Absci, BigHat Biosciences, AbCellera Biologics, Adimab and Alloy Therapeutics. Broad incumbents are GenScript and Bio-Techne. Emerging players are Ginkgo Bioworks, Generate Biomedicines and Immunome.
Does OCMS Bio have an API?
No public API is recorded for OCMS Bio.
What industry is OCMS Bio in?
OCMS Bio's product category is Therapeutic Antibody Discovery and Development. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.